India targets $1-trillion bio-economy by 2047

A biotech roadmap anchored on the BioE3 Policy, a swelling startup base and new research-funding plumbing — sketched for the centenary of independence.

What happened

• Speaking at the international conference "Vision 2047: Prosperous and Great Bharat 2.0" — hosted by IIT Roorkee with the Swadeshi Shodh Sansthan — the Union Minister of State for Science & Technology projected India's bio-economy reaching $1 trillion by 2047, the centenary of independence.
• The bio-economy is reported to have grown from $10 billion in 2014 to over $165 billion today, an annual growth of roughly 18%, with an interim target of $300 billion by 2030.
• India's biotech startup base is said to have expanded from around 50 to more than 11,000 firms over the same period.
• The roadmap rests on the BioE3 Policy (approved 2024), the new Anusandhan National Research Foundation (ANRF) with a ₹50,000-crore corpus, and a ₹1-lakh-crore Research, Development and Innovation (RDI) Fund for deep-tech.
• The Minister flagged flagship advances — Genome India, indigenous CAR-T cell therapy, mRNA vaccine platforms, India's first indigenously developed antibiotic, a National Biobank, and space biotechnology with ISRO.
• By 2047, the stated aim is for India to rank among the top three global bio-economies, with milestones pegged at 2030, 2035, 2040 and 2047.

Background & context

The announcement is not a fresh scheme launch; it is a status-and-ambition statement that stitches together a policy lineage built over the last decade. The spine of that lineage is the BioE3 Policy — full form Biotechnology for Economy, Environment and Employment — cleared by the Union Cabinet in 2024 and steered by the Department of Biotechnology (DBT) under the Ministry of Science & Technology. Where earlier biotech policy treated the sector mainly as a research and health concern, BioE3 reframes it as an industrial strategy: the goal is bio-manufacturing — using engineered biology and biofoundries to make chemicals, materials, fuels and medicines that are today produced from fossil sources. Its thematic sectors include high-value bio-based chemicals and enzymes, smart proteins and functional foods, precision biotherapeutics, climate-resilient agriculture, carbon capture and utilisation, and marine and space biotechnology.

The second pillar is the funding architecture. The Anusandhan National Research Foundation (ANRF) was set up under the ANRF Act, 2023 and subsumed the earlier Science and Engineering Research Board (SERB). ANRF is designed to seed, grow and promote research across universities and laboratories, with a planned five-year corpus in which a large share is meant to come from non-government and philanthropic sources rather than the Budget alone. Layered on top is the RDI (Research, Development and Innovation) Fund of ₹1 lakh crore, announced to channel low-cost, long-tenure capital into private-sector deep-tech and sunrise domains — the kind of patient money that a bio-manufacturing build-out needs and that ordinary commercial lending rarely supplies.

The third strand is the cluster of named flagship missions the Minister cited as proof of capability — the Genome India Project, indigenous cell-and-gene therapy, an indigenous antibiotic, the National Biobank, and adjacent deep-science programmes such as the National Quantum Mission and the Deep Ocean Mission's Samudrayaan. Together they are positioned as the building blocks of a knowledge economy whose larger 2047 markers include the Bharatiya Antariksha Station (India's planned space station) and a crewed lunar ambition.

It helps to place the named flagships in their own checklists, because each is independently examinable. Genome India is a DBT-led whole-genome-sequencing programme that built a reference database of Indian genomes drawn from a large number of distinct population groups, intended to power precision medicine and disease-risk research tailored to Indian genetic diversity. CAR-T cell therapy (chimeric antigen receptor T-cell therapy) re-engineers a patient's own immune cells to attack cancer; India's indigenous version, developed through academia–industry collaboration, was approved for clinical use and is significant for sharply lowering the cost of a treatment that runs into crores abroad. mRNA platforms are the messenger-RNA vaccine technology made familiar by the pandemic, now being localised for future vaccines. The National Biobank, linked to Genome India, is a repository of biological samples and associated data for population-scale health research. These sit alongside the National Quantum Mission (a Cabinet-approved programme of ₹6,003.65 crore for 2023–2031, under DST) and the Deep Ocean Mission, whose Samudrayaan project is developing a crewed submersible to explore the ocean floor — the marine and quantum legs of the same deep-tech push.

Compared with a peer agenda, the closest analogue is the United States' bio-economy executive order and the European Union's bioeconomy strategy, both of which also treat engineered biology and bio-based manufacturing as strategic-industrial priorities rather than purely scientific ones. India's distinguishing feature under BioE3 is the explicit pairing of the manufacturing ambition with a domestic research-funding overhaul (ANRF plus the RDI Fund) and with a dense, fast-growing startup layer, so that the policy is meant to act on the lab-to-factory pipeline at both ends at once.

For Prelims

• BioE3 Policy: Biotechnology for Economy, Environment and Employment — approved 2024; a bio-manufacturing-led growth policy under the Department of Biotechnology (DBT), Ministry of Science & Technology.
• Bio-economy size: $10 bn (2014) → $165 bn+ (today) → $300 bn by 2030 → $1 trillion by 2047; ~18% annual growth; aim of being a top-3 global bio-economy by 2047.
• Biotech startups: ~50 → 11,000+ over roughly a decade.
• ANRF: Anusandhan National Research Foundation, created by the ANRF Act 2023, replaced SERB; ₹50,000-crore corpus; promotes research across higher-education and R&D institutions.
• RDI Fund: ₹1-lakh-crore Research, Development and Innovation Fund for private deep-tech and sunrise sectors.
• Flagships named: Genome India · indigenous CAR-T cell therapy · mRNA vaccine platforms · first indigenously developed antibiotic · National Biobank · space biotech with ISRO · Deep Ocean Mission / Samudrayaan · National Quantum Mission.
• Global Innovation Index: India's rank improved from 81 to 39 (the GII is published annually by WIPO, the World Intellectual Property Organization); R&D spending reported to have more than doubled in a decade.
• 2047 markers: milestones set for 2030 / 2035 / 2040 / 2047, including the Bharatiya Antariksha Station.

Why it matters

The significance is that India is trying to reposition biotechnology from a research-and-health niche into a mainstream engine of growth, jobs and self-reliance. Bio-manufacturing addresses a concrete problem: much of the chemicals, materials and active pharmaceutical ingredients an economy consumes are made from imported fossil feedstock, which is both carbon-intensive and a strategic dependency. Engineered biology offers a route to make the same products domestically and more cleanly, which links the agenda directly to climate goals, import substitution and rural value-addition. The three "E"s in the policy name capture the intended triple dividend — Economy through high-value manufacturing, Environment through lower-carbon bio-based production and carbon capture, and Employment through a skilled bio-workforce and a startup ecosystem.

The startup and funding numbers matter because the binding constraint on deep-tech in India has historically been not ideas but patient capital and translational infrastructure — exactly the gap ANRF and the RDI Fund are meant to close. A wider growth-policy reading also matters: a knowledge-and-innovation economy is, in principle, less land- and emissions-intensive per rupee of output than heavy industry, so success here could ease the tension between growth and decarbonisation. The honest counter-point, which an exam answer should carry, is that these are projections and announced corpora; the share of private and philanthropic money ANRF is designed to mobilise, the speed of disbursal, regulatory clarity for gene-edited products, the still-low overall R&D-spend-to-GDP ratio, and the gap between a policy target and notified, financed outcomes all remain open questions. A target stated for 2047 is an aspiration that must survive two decades of execution.

For Mains